People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Pharmaceuticals, Other, Healthtech, Other Technology, Other Health Care, Computers
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VBI Vaccines Inc/BC | — | Pharmaceuticals | Series A | $41.6M | $145.6M | 2016 |
| Vapor Corp. | — | Other | Series A | $16.5M | $26.5M | 2015 |
| Motus GI Medical Technologies, Ltd. | — | Healthtech | Series A | $13.8M | $310.8M | 2016 |
| DesignLine International Corp | — | Other Technology | Seed | $4.2M | $107.3M | 2009 |
| Fresenius Vascular Care Memphis MSO, LLC | — | Other Health Care | Seed | $3.5M | $87.3M | 2012 |
| Lucidity Consulting Group LP | — | Computers | Seed | $2.5M | $5.0M | — |
| International Money Management, Inc. | — | Other | Seed | $1.9M | $9.8M | 2010 |
| RallyCorp, Inc. | — | Other Technology | Pre-Seed | $770K | $11.1M | 2022 |
| St. John CV Co-Management Company, LLC | — | Hospitals and Physicians | Pre-Seed | $450K | $12.9M | 2011 |
James Martin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Martin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| David Anderson | 1 | 21 |
| Steve Gillis | 1 | 13 |
| Gary Jacobs | 1 | 11 |
| Paul Toomey | 1 | 10 |
| Ronald Rogers | 1 | 9 |
| Steven Rubin | 1 | 7 |
| Scott Requadt | 1 | 5 |
| DAVID HOCHMAN | 1 | 5 |
| Jeff Baxter | 1 | 4 |
| David E. Anderson | 1 | 3 |
| Tomer Kariv | 1 | 3 |
| Mark Pomeranz | 1 | 3 |
| Egidio Nascimento | 1 | 3 |
| FRANCISCO DIAZ-MITOMA | 1 | 3 |
| Darren Sherman | 1 | 3 |
| William C. Glasier | 1 | 2 |
| Blaine McKee | 1 | 2 |
| Gary C. Robertson | 1 | 2 |
| Sanjay Batra | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.